danalcock, Author at European Medical Journal - Page 12 of 15

Conquering generational differences in HCP marketing

What are the generation differences in how HCPs want to talk to pharma? Three generations of doctors share their thoughts.

Mina Makar on tackling unmet patient needs

AstraZeneca’s Mina Makar talks about solving unmet needs and how to champion the patient perspective.

The Twitter scandal that scared off pharma marketers

Many top pharma companies have cut their Twitter ad spend after the Eli Lilly scandal, but should they take a risk and return?

5 ways pharma can ensure omnichannel success

Roche’s Davidek Herron offers five top tips for pharma teams striving for omnichannel excellence.

Mastering medical affairs

Medical affairs is becoming increasingly complex, but industry-academia collaboration aims to tackle this head on.

The brains behind neurological breakthroughs

The recent approval of lecanemab is a win for Alzheimer’s patients, but how can pharma ensure access?

Eli Lilly improves cold chain capacity

Eli Lilly has pledged over $1m to improve cold chain capacity for insulin in low- to middle-income countries.

Pharma in Poland

Travel to Poland to discover the factors driving its pharmerging status and access to medicine challenges.

Reflections and predictions for 2023

Explore the key trends and themes industry experts predict will be in store for pharma over the next 12 months.

Mental health matters in pharma's approach to care

Treatments for cancer are continuously advancing, but pharma must also focus on supporting patients’ mental health.